secwatch.observer — SEC 8-K summary
======================================

Issuer:     KYNTRA BIO, INC. (KYNB)
CIK:        0000921299
Form:       8-K
Filed at:   2025-06-09T23:59:59+00:00
Accession:  0000950170-25-083676
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 5.07, 5.02, 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FibroGen shareholders approve reverse stock split; appoints Michael Kauffman to board
--------------------------------------------------------------------------------

- Shareholders approved reverse stock split (1:10-1:25) to meet Nasdaq listing requirement; 85% voted in favor.
- Jeffrey L. Edwards re-elected as Class II director with 92.25% of votes cast.
- Dr. Michael Kauffman appointed to board, will serve on Audit and Compensation Committees; term expires 2026.
- Director Aoife Brennan resigned effective June 4, 2025, no disagreement with company.
- Second amendment to financing agreement lowered minimum cash balance from $27M to $22.5M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/921299/000095017025083676/0000950170-25-083676-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/921299/000095017025083676/fgen-20250604.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-083676

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer